484 related articles for article (PubMed ID: 34934057)
1. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
[TBL] [Abstract][Full Text] [Related]
2. PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth.
Singh N; Padi SKR; Bearss JJ; Pandey R; Okumura K; Beltran H; Song JH; Kraft AS; Olive V
Mol Oncol; 2020 May; 14(5):974-990. PubMed ID: 32146726
[TBL] [Abstract][Full Text] [Related]
3. BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Kim DH; Sun D; Storck WK; Welker Leng K; Jenkins C; Coleman DJ; Sampson D; Guan X; Kumaraswamy A; Rodansky ES; Urrutia JA; Schwartzman JA; Zhang C; Beltran H; Labrecque MP; Morrissey C; Lucas JM; Coleman IM; Nelson PS; Corey E; Handelman SK; Sexton JZ; Aggarwal R; Abida W; Feng FY; Small EJ; Spratt DE; Bankhead A; Rao A; Gesner EM; Attwell S; Lakhotia S; Campeau E; Yates JA; Xia Z; Alumkal JJ
Clin Cancer Res; 2021 Sep; 27(17):4923-4936. PubMed ID: 34145028
[TBL] [Abstract][Full Text] [Related]
4. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
Li L; Dang Q; Xie H; Yang Z; He D; Liang L; Song W; Yeh S; Chang C
Oncotarget; 2015 Jun; 6(16):14179-90. PubMed ID: 25895025
[TBL] [Abstract][Full Text] [Related]
5. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
[TBL] [Abstract][Full Text] [Related]
6. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
7. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.
Zhang B; Zhang M; Shen C; Liu G; Zhang F; Hou J; Yao W
Cell Death Dis; 2021 Sep; 12(10):856. PubMed ID: 34545063
[TBL] [Abstract][Full Text] [Related]
8. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
Ci X; Hao J; Dong X; Choi SY; Xue H; Wu R; Qu S; Gout PW; Zhang F; Haegert AM; Fazli L; Crea F; Ong CJ; Zoubeidi A; He HH; Gleave ME; Collins CC; Lin D; Wang Y
Cancer Res; 2018 May; 78(10):2691-2704. PubMed ID: 29487201
[TBL] [Abstract][Full Text] [Related]
9. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
10. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
VanDeusen HR; Ramroop JR; Morel KL; Bae SY; Sheahan AV; Sychev Z; Lau NA; Cheng LC; Tan VM; Li Z; Petersen A; Lee JK; Park JW; Yang R; Hwang JH; Coleman I; Witte ON; Morrissey C; Corey E; Nelson PS; Ellis L; Drake JM
Mol Cancer Res; 2020 Aug; 18(8):1176-1188. PubMed ID: 32461304
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression.
Zhang M; Sun Y; Huang CP; Luo J; Zhang L; Meng J; Liang C; Chang C
Cell Death Dis; 2021 Sep; 12(10):855. PubMed ID: 34545067
[TBL] [Abstract][Full Text] [Related]
12. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
13. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
14. Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
Tiwari R; Manzar N; Bhatia V; Yadav A; Nengroo MA; Datta D; Carskadon S; Gupta N; Sigouros M; Khani F; Poutanen M; Zoubeidi A; Beltran H; Palanisamy N; Ateeq B
Nat Commun; 2020 Jan; 11(1):384. PubMed ID: 31959826
[TBL] [Abstract][Full Text] [Related]
15. A novel mechanism of SRRM4 in promoting neuroendocrine prostate cancer development via a pluripotency gene network.
Lee AR; Gan Y; Tang Y; Dong X
EBioMedicine; 2018 Sep; 35():167-177. PubMed ID: 30100395
[TBL] [Abstract][Full Text] [Related]
16. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
17. Loss of Long Noncoding RNA
Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
[TBL] [Abstract][Full Text] [Related]
18. The β
Braadland PR; Ramberg H; Grytli HH; Urbanucci A; Nielsen HK; Guldvik IJ; Engedal A; Ketola K; Wang W; Svindland A; Mills IG; Bjartell A; Taskén KA
Mol Cancer Res; 2019 Nov; 17(11):2154-2168. PubMed ID: 31395667
[TBL] [Abstract][Full Text] [Related]
19. Gene Expression Signature Predictive of Neuroendocrine Transformation in Prostate Adenocarcinoma.
Ostano P; Mello-Grand M; Sesia D; Gregnanin I; Peraldo-Neia C; Guana F; Jachetti E; Farsetti A; Chiorino G
Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32041153
[TBL] [Abstract][Full Text] [Related]
20. Long Non-coding RNA AFAP1-AS1 Facilitates Prostate Cancer Progression by Regulating miR-15b/IGF1R Axis.
Liu B; Jiang HY; Yuan T; Zhou WD; Xiang ZD; Jiang QQ; Wu DL
Curr Pharm Des; 2021; 27(41):4261-4269. PubMed ID: 34126893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
